

AperTO - Archivio Istituzionale Open Access dell'Università di Torino

**Post-treatment recovery of suboptimal DNA repair capacity and gene expression levels in colorectal cancer patients**

**This is the author's manuscript**

*Original Citation:*

*Availability:*

This version is available <http://hdl.handle.net/2318/1532160> since 2016-06-29T15:01:43Z

*Published version:*

DOI:10.1002/mc.22141

*Terms of use:*

Open Access

Anyone can freely access the full text of works made available as "Open Access". Works made available under a Creative Commons license can be used according to the terms and conditions of said license. Use of all other works requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.

(Article begins on next page)

# Post-Treatment Recovery of Suboptimal DNA Repair Capacity and Gene Expression Levels in Colorectal Cancer Patients

Jana Slysokova,<sup>1,2\*</sup> Francesca Cordero,<sup>3</sup> Barbara Pardini,<sup>4</sup> Vlasta Korenkova,<sup>5</sup> Veronika Vymetalkova,<sup>1,2</sup> Ludovit Bielik,<sup>1,2,6</sup> Ludmila Vodickova,<sup>1,2</sup> Pavel Pitule,<sup>7</sup> Vaclav Liska,<sup>7,8</sup> Vit Martin Matejka,<sup>8</sup> Miroslav Levy,<sup>9</sup> Tomas Buchler,<sup>9</sup> Mikael Kubista,<sup>5,10</sup> Alessio Naccarati,<sup>1,4</sup> and Pavel Vodicka<sup>1,2\*</sup>

<sup>1</sup>Institute of Experimental Medicine, ASCR, Prague, Czech Republic

<sup>2</sup>First Faculty of Medicine, Institute of Biology and Medical Genetics, Prague, Czech Republic

<sup>3</sup>University of Torino, Torino, Italy

<sup>4</sup>Human Genetics Foundation (HuGeF), Torino, Italy

<sup>5</sup>Institute of Biotechnology, ASCR, Prague, Czech Republic

<sup>6</sup>Faculty of Science, Charles University, Prague, Czech Republic

<sup>7</sup>Biomedical Centre, Medical School Pilsen, Charles University in Prague, Pilsen, Czech Republic

<sup>8</sup>Clinic of Oncology and Radiotherapy, Faculty Hospital in Pilsen, Charles University, Pilsen, Czech Republic

<sup>9</sup>Thomayer Hospital and First Faculty of Medicine, Charles University, Prague, Czech Republic

<sup>10</sup>TATAA Biocenter, Goteborg, Sweden

DNA repair in blood cells was observed to be suboptimal in cancer patients at diagnosis, including colorectal cancer (CRC). To explore the causality of this phenomenon, we studied the dynamics of DNA repair from diagnosis to 1 yr follow-up, and with respect to CRC treatment. Systemic CRC therapy is targeted to DNA damage induction and DNA repair is thus of interest. CRC patients were blood-sampled three times in 6-mo intervals, starting at the diagnosis, and compared to healthy controls. DNA repair was characterized by mRNA levels of 40 repair genes, by capacity of nucleotide excision repair (NER), and by levels of DNA strand breaks (SBs). NER and base excision repair genes were significantly under-expressed ( $P < 0.016$ ) in patients at diagnosis compared to controls, in accordance with reduced NER function ( $P = 0.008$ ) and increased SBs ( $P = 0.015$ ). Six months later, there was an increase of NER capacity, but not of gene expression levels, in treated patients only. A year from diagnosis, gene expression profiles and NER capacity were significantly modified in all patients and were no longer different from those measured in controls. All patients were free of relapse at the last sampling, so we were unable to clarify the impact of DNA repair parameters on treatment response. However, we identified a panel of blood DNA repair-related markers discerning acute stage of the disease from the remission period. In conclusion, our results support a model in which DNA repair is altered as a result of cancer. © 2014 Wiley Periodicals, Inc.

Key words: Colorectal cancer; DNA instability; DNA repair; biomarker; anti-cancer therapy; follow-up study

## INTRODUCTION

Colorectal cancer (CRC) is one of the most frequently occurring malignancies in Western countries. The genetic basis of hereditary forms (~6% of all cases) is relatively well explored while for sporadic forms (~75% of all cases) there is still a lack of knowledge about the genetic–epigenetic–environmental triggers of the disease. More importantly, CRC has high mortality worldwide due to the insufficient treatment efficacy and a lack of predictive markers [1]. Only approximately half of CRC patients will be cured using currently available therapies [2]. A commonly used conventional regimen for CRC treatment is based on the synergistic action of two DNA-damaging agents: 5-fluorouracil (5FU) and oxaliplatin. In response to this treatment, cells activate a range of resistance-promoting mechanisms including the DNA repair pathways [3]. Some of the optimal biomarkers might be thus found within the DNA repair network.

Abbreviations: 5FU, 5-fluorouracil; BPDE, (+)-anti-Benzo[a]pyrene-7,8-dihydrodiol-9,10-epoxide; BER, base excision repair; CRC, colorectal cancer; CV, coefficient of variation; DDR, DNA damage response; HR, homologous recombination; MMR, mismatch repair; NER, nucleotide excision repair; PBMCs, peripheral blood mononuclear cells; PCA, principal component analysis; SBs, strand breaks.

Alessio Naccarati and Pavel Vodicka contributed equally to this work.

The authors declare they have no competing interests.

Grant sponsor: CZ GACR; Grant numbers: GAP304/10/1286; GAP 304/12/1585; P304/11/P715; Grant sponsor: IGA; Grant number: NT14329-3; Grant sponsor: BIOCEV; Grant number: CZ.1.05/1.1.00/02.0109 from ERDF

\*Correspondence to: Department of Molecular Biology of Cancer, IEM ASCR, Videnska 1083, Prague 14220, Czech Republic.

Received 31 October 2013; Revised 27 January 2014; Accepted 6 February 2014

DOI 10.1002/mc.22141

Published online 3 March 2014 in Wiley Online Library (wileyonlinelibrary.com).

The present study represents a continuation of our previous report, where we showed that peripheral blood mononuclear cells (PBMCs) collected from CRC patients at the time of diagnosis exhibited elevated genetic instability. Specifically, they had increased levels of DNA strand breaks (SBs) and low DNA repair capacity accompanied by altered expression of repair genes [4]. The suboptimal DNA repair capacity in PBMCs of cancer patients is now well documented and observed in multiple cancer types [4]. Thus, there is a large body of evidence obtained in case-control studies supporting the association between cancer and a decrease in the ability of blood cells to protect against DNA damage. However, a sampling of the patients at one time point does not bear information about the causality of this phenomenon and so it remains to be established whether low DNA repair is one of the susceptibility factors for sporadic CRC, or it is a consequential effect of the disease. On the other hand, it is known that DNA repair capacity detectable in PBMCs is significantly related to the repair capacity of colorectal tissue [5,6]. These observations give more confidence for using blood as a surrogate for cancer-target tissue to study DNA repair involvement in CRC. Subsequently, a few recent studies provided evidence that tumor tissue maintains comparable base excision repair (BER) capacity and slightly elevated capacity of nucleotide excision repair (NER) as compared to adjacent healthy colorectal mucosa, although there is a differential mRNA expression of DNA repair genes [6–8]. Impaired excision repair, thus, may not contribute to the malignant transformation of the colon, but rather might be involved in the treatment response of the patients.

Conventional therapy of CRC, based on the mutagenic properties of anticancer drugs, is expected to be more harmful to fast growing tumor cells than to normal cells. However, details of the effects of radiotherapy and chemotherapy on the cellular and molecular functions of the tumor and normal cells are still unexplored. Almost all DNA repair pathways are presumably involved in the cellular response to CRC treatment. 5FU-mediated DNA lesions are recognized by the BER and the mismatch repair (MMR) systems [9]. Oxaliplatin binds to nucleobases forming intra- and inter-strand crosslinks. The former are eliminated mainly by the NER pathway while the latter require NER together with cross-link repair activity, translesion synthesis, and homologous recombination repair (HR) [10]. Understanding the involvement of DNA repair processes in the response of cancer cells to antineoplastic drugs is crucial for the design of improved therapy regimens and for the prediction of therapeutic response in CRC.

The present exploratory study was aimed to address several questions: (i) Do variations in DNA repair contribute to the risk of developing sporadic CRC, or are they rather a consequence of the systemic disease? (ii) Is the DNA repair response to CRC treatment

measurable at the mRNA/functional level? (iii) Is it induced or suppressed by the systemic genotoxic exposure mediated by chemotherapy? In an attempt to answer these questions, we have designed a prospective study in which sporadic CRC patients were blood-sampled at the diagnosis (i.e., active disease), 6 mo, and 1 yr later (i.e., covering the tumor resection, administration of chemotherapy, either neoadjuvant or adjuvant, and remission) and were compared with an healthy population. The dynamics of DNA repair over a 1 yr period and with respect to ongoing CRC treatment were analyzed. All main repair pathways including excision repair (BER, NER, and MMR), repair of double-strand breaks (HR and non-homologous end joining), and DNA damage response (DDR) were characterized at gene expression levels. NER, the most deregulated pathway in patients observed by us, was also studied using a functional assay and through measuring SBs accumulation.

## MATERIALS AND METHODS

### Study Population

Incident CRC cases were recruited in the Czech Republic between 2008 and 2010. Patients were newly diagnosed and histologically confirmed for CRC. Eighty-three patients were initially recruited for the study but only 39 (47%) attended all the three planned blood samplings. Reasons for dropout were: (i) 7 (8%) patients died before third sampling, (ii) 10 (12%) patients moved and were treated in other hospitals or interrupted therapy for unspecified reasons, (iii) 19 (23%) patients missed one out of the three samplings or did not attend regular hospital follow-up at agreed times, or the material provided did not meet the quality standards required, and (iv) 8 (10%) patients were excluded because they were found not to be primary cancer cases. No other selection of patients was performed. Forty-seven controls were recruited among individuals who had never been diagnosed with any cancer and did not manifest any relevant systemic disease, nor had any known significant exposure to potentially harmful chemicals. Study subjects were all of Caucasian origin. They signed a written informed consent with the study in accordance with the Helsinki declaration. The Ethics committees of participating hospitals approved the study. Trained personnel interviewed the study subjects using a structured questionnaire for lifestyle habits, body mass index, diabetes, and family/personal history of cancer. Expression analysis and functional assays could not be performed on all patients, due to various reasons, that is, viability of PBMCs or quality of RNA. For each analysis, the actual number of examined cases is therefore specified.

### Study Design

Blood samples were collected from patients three times: at diagnosis, that is, before tumor resection and

administering any therapy (T0); 6 mo after tumor resection, that is, approximately 6 mo from administration of chemotherapy (T1); and after 1 yr, during the regular follow-up appointment (T2). At T1 all patients had completed the planned chemotherapy, except for seven patients who received chemotherapy for additional 1 or 2 mo. In eight patients, no therapy was administered. At T2, all patients were free of relapse.

#### Blood Processing

Blood samples were drawn into heparin and EDTA vacutainers, and kept at 4°C until processed within 3 h. PBMCs from EDTA tubes were isolated on Ficoll-Paque PLUS (GE Healthcare Life Sciences, Prague, Czech Republic) and stored in TRIzol (Invitrogen, Carlsbad, CA) at -80°C until RNA extraction. PBMCs from heparin tubes were isolated on Histopaque-1077 (Sigma-Aldrich, St. Louis, MO), counted, suspended in full medium (RPMI 1640, 2 mM L-glutamine, 10% FBS, 0.2% penicillin/streptomycin, 1.5% phytohemagglutinin) and incubated at 37°C for 20 h to stimulate mitosis. PBMCs were then processed for DNA damage and DNA repair analysis.

#### DNA Strand Breaks

The level of SBs in DNA was evaluated by the alkaline comet assay [11]. Experimental conditions were as follows: lysis (2.5 M NaCl, 100 mM EDTA, 10 mM Tris, 1% TritonX-100, 10% DMSO, pH 10,  $\geq 1$  h, 4°C), alkali treatment (300 mM NaOH, 1 mM EDTA, pH 13, 20 min, 4°C), electrophoresis (300 mM NaOH, 1 mM EDTA, pH 13, 20 min, 4°C, 1.3 V/cm), and neutralization (0.4 M Tris-HCl, pH 7.5,  $2 \times 10$  min). Data are reported as tail DNA%, determined as an average of 100 randomly selected comets from two parallel slides per experimental point. Repeatability of the assay was checked by repeated measuring of 12 randomly chosen samples and obtained values were in agreement (Spearman's  $R = 0.76$ ,  $P = 0.028$ ).

#### Nucleotide Excision Repair Capacity

NER capacity was analyzed as the level of SBs generated by the incision of (+)-anti-Benzo[a]pyrene-7,8-dihydrodiol-9,10-epoxide (BPDE)-adducts in cultured PBMCs of study participants. The detailed protocol is described in Slyska et al. [11]. Briefly, PBMCs were treated with 1  $\mu$ M of BPDE for 30 min at 37°C. BPDE was washed out and PBMCs were further cultured and harvested immediately after the treatment and at 1, 2, and 4 h after the treatment. Untreated PBMCs were cultured in parallel. For each time point, the SBs level of the untreated PBMCs was subtracted. The NER capacity was expressed as the difference between the level of SBs measured immediately after the BPDE treatment, and the highest level of SBs detected within 4 h of culturing. Data are presented as tail DNA%. Repeatability of the assay was checked by repeated measuring of 16 samples and

obtained results were in agreement (Spearman's  $R = 0.61$ ,  $P = 0.012$ ).

#### Gene Expressions

A panel of 40 genes (Supplementary Table S1) were selected from the list of all known DNA repair genes [12]. Total RNA was isolated using TRIzol (Invitrogen). RNA integrity was between 8.0 and 10.0 units. cDNA was synthesized from 0.5  $\mu$ g of RNA using the RevertAid™ First strand cDNA synthesis kit (Fermentas, Ontario, Canada). cDNA was preamplified and qPCR was performed using the BioMark™ HD System (Fluidigm) and using FAM-MGB assays (Primer Design, Southampton, UK) as described previously [6]. *TOP1* was the reference gene selected by Normfinder using GenEx Enterprise software (MultiD, Goteborg, Sweden). Data were converted to relative quantities and transformed to log<sub>2</sub> scale. The repeatability of gene expression assays was calculated by mixed ANOVA, comparing the values obtained in two different experiments in 2 days for each assay. All assays showed high degree of precision. The results are reported in Supplementary Table S1 for each assay separately.

#### Data Analysis

Statistical analysis was conducted using R environment version 2.15 (open tool). Gene expression data were pre-processed with GenEx Enterprise. DNA damage and DNA repair capacity were consistent with the Gaussian distribution, and so were the gene expression data when log transformed. Student's *t*-test, paired *t*-test, ANOVA and Pearson's rank correlation coefficient were used to compare means and calculate bivariate correlations. Statistical tests were performed at 5% level of statistical significance. Gene expression data are presented as fold-changes relative to the reference samples, calculated using linear models and the empirical Bayes method as implemented in the "limma" package in the Bioconductor suite (open tool). *P*-values were adjusted according to the Benjamini-Hochberg method. Principal Component Analysis (PCA), Dynamic PCA, Hierarchical Clustering (HCL), and Kohonen self-organizing map analysis (SOM) of size  $2 \times 1$ , with parameters: 0.1 learning rate, 2 neighbors, and 3000 iterations were used to analyze gene expression profiles between patients and controls and between different samplings in patients. The *k*-means algorithm was used to classify genes into clusters based on their expression profiles over the three time points, considering the patients clinical characteristics.

## RESULTS

#### Study Population

Patients and controls did not differ significantly for any recorded confounders, except for family history of cancer, which was more prevalent among patients ( $P = 0.01$ ). The clinical, biological, and lifestyle

characteristics of the study population, as well as an overview of the administered therapies, are summarized in Table 1. All patients underwent surgical resection of the tumor. Eighteen patients (46%) received neoadjuvant therapy prior to resection. Neoadjuvant therapy included the following regimens: two patients received radiotherapy (6 MeV X-rays, 45–46 Gy total dose in 23–25 fractions), three patients received pre-operative chemotherapy without radiotherapy (FOL-FOX or capecitabine), and 13 patients received a combined regimen. Twenty-two patients (56%) received adjuvant systemic therapy; nine of them were given 5FU-based therapy, while 13 received a combination of 5FU and oxaliplatin. Adjuvant therapy was given over a period of 1–8 mo. Tumor relapse after the treatment was not detected in any of the patients. Eight patients did not receive any systemic treatment.

#### Case–Control Study

##### DNA repair genes expression

Twenty-seven CRC cases and 38 controls were analyzed for the expression of 40 DNA repair genes,

sampled at diagnosis and before any treatment intervention (T0). Patients had different expression levels of BER and NER genes compared to controls: four out of nine BER genes (*APEX1*, *NTHL1*, *PARP1*, and *MPG*) and 10 out of 19 NER genes (*RPA1*, *RPA2*, *RPA3*, *CDK7*, *DDB1*, *DDB2*, *XPA*, *XPD*, *ERCC8*, and *RAD23B*) had significantly decreased levels in patients. Only *LIG3* (BER) was increased in patients as compared to controls. Fold-changes and *P* values are reported in Supplementary Table S2. The dendrogram in Figure 1, performed by HCL, discriminates between patients and controls by expression profiles of all 40 repair genes. The same discrimination was observed for the NER genes only (data not shown).

##### NER capacity and SBs

Functional assays were performed for 31 CRC cases and 38 controls. NER capacity was significantly lower in the CRC patients analyzed at T0 compared to the controls (mean  $\pm$  SD;  $9.9 \pm 7.5$  and  $15.5 \pm 13.6$ , respectively; *t*-test *P* = 0.008; Figure 2A), and the patients had significantly higher levels of SBs than

Table 1. Study Population Characteristics

Characteristics	Category	CRC patients (n = 39)	Controls (n = 47)	P-value
Sex	Female	15	24	0.25
	Male	24	23	
Age (years)	Mean $\pm$ SD	64.5 $\pm$ 10.5	64.2 $\pm$ 13.7	0.94
	Median	65	62.5	
	Range	32–81	33–87	
Body mass index	Mean $\pm$ SD	27.6 $\pm$ 4.4	26.1 $\pm$ 3.6	0.14
	Median	27.1	25.1	
	Range	17.6–37.3	20.7–34.7	
Smoking status	Non-smoker	27	38	0.72
	Smoker	7	8	
Alcohol consumption	No	11	17	0.74
	Yes	22	29	
Diabetes	No	26	43	0.08
	Yes	7	3	
Cancer in family	No	13	31	<b>0.01</b>
	Yes	21	15	
CRC in family	No	28	36	0.55
	Yes	3	6	
Tumor localization	Colon + rectosigmoideum	19	—	
	Rectum	20	—	
TNM staging	I	6	—	
	II	20	—	
	III	4	—	
	IV	9	—	
Grade	I	2	—	
	II	25	—	
	III	12	—	
Therapy	None	8	—	
	Neoadjuvant	18	—	
	Adjuvant	22	—	
	Neoadjuvant + adjuvant	11	—	
Regimen of adjuvant therapy	5FU	9	—	
	5FU + oxaliplatin	13	—	

Significant differences are shown in bold.




Figure 1. Hierarchical clustering of CRC patients sampled at the diagnosis (T0) and healthy controls according to the expression profiles of 40 DNA repair genes.

the controls ( $25.6 \pm 21.4$  and  $13.9 \pm 13.8$ ,  $t$ -test  $P=0.015$ ; Figure 2B).

#### Longitudinal Study

Changes in DNA repair genes expression during 1 yr of follow-up

Twenty-seven patients analyzed at T0 were sampled two more times with at 6-mo intervals (T1 and T2). Expression of the majority of the studied genes did not change appreciably between T0 and T1 but substantially changed at T2. PCA of all 40 studied genes revealed similar expression patterns of samples obtained at T0 and T1 while the expression at T2 had a significantly different pattern and the samples were organized in a distinct cluster together with controls (Figure 3). To identify differentially expressed genes that best discriminate both clusters, dynamic PCA in combination with Kohonen SOM was used. Six genes (BER: *LIG3*, NER: *RPA3*, *CDK7*, *DDB2*, HR: *NBN*, and DDR: *CHEK2*) were found to be responsible for the aggregation of patients into two distinct clusters (Figure 4).

DNA repair genes expression over time in relation to therapy

The  $k$ -means algorithm was used to correlate the gene expression levels over time to treatment

(untreated vs. treated patients) and to the different regimens of adjuvant therapy (5FU vs. 5FU + oxaliplatin). Four main clusters were generated based on the  $Cq$  delta values representing the differences between T1–T0 and T2–T1 (Supplementary Figure 1). A trend line for the four clusters was constructed and each cluster was also represented by a heatmap showing for each gene the expression values over time. The heatmap revealed great variability in the expression dynamics of the studied genes, particularly in the T1–T2 interval. The expression of the majority of the genes did not differ between treated and untreated patients, except for three genes. The BER gene *MUTYH* mRNA levels increased in adjuvantly treated patients but was reduced in untreated. *POLB* (BER) and *XPB* (NER) had constant expression over time in treated patients, but were upregulated from T0 to T2 in untreated patients (Supplementary Figure 1). No differences were observed between therapy regimens of 5FU + oxaliplatin versus 5FU only.

Changes in NER capacity and SBs during 1 yr of follow-up

NER capacity and SBs were compared between the three samplings in a group of 27 patients. NER capacity increased significantly between T0 and T1, and did not change further between T1 and T2 (T0:  $9.9 \pm 7.5$ , T1:  $15.8 \pm 13.2$ , T2:  $11.2 \pm 6.9$ , ANOVA  $P=0.002$ ; Figure 2A). NER capacity at T1 and T2 did




Figure 2. NER capacity (A) and SBs (B) in CRC patients measured in three consecutive samplings at 6-mo intervals starting from the diagnosis (T0, T1, and T2) and of healthy controls. Figure shows mean  $\pm$  SD and ANOVA *P* values.

not differ from that in the controls (*t*-test *P* = 0.87 and *P* = 0.10, respectively). SBs increased gradually, with the largest rise being observed between T1 and T2 (T0:  $25.6 \pm 21.4$ , T1:  $29.2 \pm 17.1$ , T2:  $41.8 \pm 12.8$ , ANOVA

*P* < 0.001; Figure 2B). At all the three time points, SBs level was significantly higher in cases than in the controls (*t*-test *P* < 0.001). *P* values for comparisons between each sampling in patients computed by paired *t*-test are reported in Supplementary Table S3.

#### NER capacity and SBs over time in relation to therapy

NER capacity increased over time in adjuvantly treated patients (ANOVA *P* = 0.01), while the trend in untreated patients was not significant (ANOVA *P* = 0.08; Figure 5A). This trend was significant also for patients receiving neoadjuvant treatment (ANOVA *P* = 0.02). No differences in NER capacity were seen after stratification for treatment regimen: 5FU (ANOVA *P* = 0.07) and 5FU + oxaliplatin (ANOVA *P* = 0.19). SBs increased over time in all patients irrespectively of the treatment. Figure 5B displays SBs values over time in untreated (ANOVA *P* < 0.001) and adjuvantly treated patients (ANOVA *P* = 0.05), and the same trend of increasing SBs was observed for neoadjuvantly treated patients (ANOVA *P* = 0.04). By stratifying adjuvantly treated patients, it was found that the degree of SBs was not affected by 5FU treatment (ANOVA *P* = 0.78), but increased with the 5FU + oxaliplatin regimen (T0:  $19.0 \pm 22.4$ , T1:  $28.6 \pm 21.6$ , T2:  $42.4 \pm 14.1$ , ANOVA *P* = 0.047). Paired *t*-test *P* values for comparisons between each sampling in patients stratified for different treatments are reported in Supplementary Table S3.

#### DISCUSSION

The present study was focused on characterizing differences in DNA repair between CRC patients and cancer-free population. Subsequently, defined impairment of DNA repair in cancer patients was




Figure 3. Principal component analysis of gene expression levels of 40 DNA repair genes analyzed in CRC patients at three time points (T0, T1, and T2) and in control population.




Figure 4. Identification of the most significant genes responsible for division of samples into two separate clusters. The color coding is the identical with the one in Figure 3. Kohenen self-organizing map analysis (A) and three-dimensional principal component analysis (B) based on the mean-centered differential gene expression profiles of *LIG3*, *RPA3*, *CDK7*, *DDB2*, *NBN*, and *CHEK2*.

followed-up during a post-treatment period, with samplings at 6 mo after tumor resection and chemotherapy administration, and an additional sample 6 mo later. This study should reflect changes

in the DNA repair proficiency in patients under the genotoxic stress of the anti-cancer treatment. We have characterized DNA repair processes in blood samples of CRC patients. PBMCs are considered to be representatives of the general condition of the organism and we have shown that their DNA repair capacity reflects that of colonic mucosa [6]. Therefore, PBMCs represent potential surrogates of CRC target tissue, with the great advantage that if repeated biopsies are difficult to obtain, repeated blood samplings are feasible and much better suited for therapy monitoring.

#### DNA Repair in Patients Versus Controls

In the present case-control study, we have identified genes that were differentially expressed between CRC patients at diagnosis and controls. Several BER and the majority of the studied NER genes were under-expressed in CRC patients. We evaluated NER also on functional level to determine if the reduced mRNA expression levels were concomitant with reduced functional capacity of the pathway. Decreased NER capacity in patients was confirmed and was accompanied by increased levels of SBs. These findings are consistent with our previous observations of CRC patients sampled at diagnosis having lower NER capacity and higher DNA damage than controls [4]. A large body of evidence is now available on impaired NER in patients diagnosed with different types of malignancies, as reviewed by us [4] and by [13]. However, these are case-control studies with no further indication on causality of this phenomenon in relation to cancer onset.

#### DNA Repair in Patients' Follow-Up

We designed a longitudinal study to follow up the CRC patients from diagnosis to 1 yr in three different




Figure 5. Subgroups of untreated patients and adjuvantly treated patients compared for changes in NER capacity (A) and DNA SBs levels (B) as analyzed in three consecutive samplings obtained at 6-mo intervals (T0, T1, and T2). Figure shows mean  $\pm$  SD and ANOVA *P* values.



samplings obtained 6 mo apart. Interestingly, while expression profiles at diagnosis and 6 mo later were substantially similar for the 40 analyzed genes, significant changes in mRNA levels were observed at the third sampling obtained 12 mo after diagnosis. At that time point, patients were considered “cured” and there were no cases in the study group that relapsed. We can hypothesize that the expression profiles of DNA repair genes reflected the disease activity. Indeed, patients’ expression profiles a year from diagnosis were comparable to those of the healthy subjects. NER capacity showed a similar tendency. From reduced level in patients at the time of diagnosis, NER capacity increased during the post-treatment period between diagnosis and 1 yr later, eventually matching the level of the healthy subjects. Different results were obtained for the comparison of SBs levels overtime in patients. SBs were twofold higher in patients at diagnosis compared to controls, and their level further increased reaching threefold difference a year from diagnosis. This accumulation of SBs was independent of the presence of the tumor in the body as well as treatment with DNA-damage inducing drugs. Possibly some other clinical or biological parameters that we have not controlled for may be responsible for this late effect.

The dynamics of DNA repair capacity were previously studied in healthy individuals by comparing BER and NER activities in six repeated samplings over a 5-mo period [14]. The values positively correlated and the coefficient of variation (CV) was 27% for BER and 49% for NER, respectively. Intra-individual variability of NER capacity was evaluated also by us in a pilot study of 16 healthy subjects sampled twice 6 mo apart. Values of two independent samplings significantly positively correlated and the CV of 20% was much lower than the inter-individual variability observed in our recent study on 340 healthy individuals (CV 84% for BER and 90% for NER; unpublished data). Similar observations were also reported in the study by Vogel et al [15]. DNA repair capacity thus seems to be a characteristic parameter for each individual (but having a rather high variability across the general population). Here, we showed that this hypothesis based on healthy population is not applicable in cancer patients. In fact, in the present study we showed that cancer patients undergoing anti-cancer treatment displayed significant changes in DNA repair overtime, between the diagnosis and the recovery period 1 yr later.

Only a few studies have examined DNA repair prospectively to elucidate the role of this process in cancer development. The expression levels of DNA repair genes *OGG1*, *NEIL1*, *MUTYH*, *ERCC1*, and *XPB* were not associated with subsequent risk of getting lung cancer, and it was proposed that mRNA levels should be regarded as a biomarker of exposure to oxidative stress rather than a marker of inborn DNA repair capacity [16,17]. Quite the opposite was

concluded by Paz-Elizur et al. [18], who analyzed OGG1 activity in lung cancer patients at 1 yr follow-up starting at diagnosis and reported a lack of an effect of the tumor on OGG1 activity, suggesting the inherent characteristic of this parameter. Our study, in contrary to previous ones, used a multivariate approach to search for biomarkers that best characterize an individuals’ DNA repair status. It is becoming imperative to classify diseases not on the basis of a single biomarker, but on the basis of a set of molecular markers [19]. This is expected to be more robust and reliable than using any single biomarker because of their generally high variability. Changes in individual parameters will not necessarily result in a significant change of the entire pattern. Using this approach, we have seen that a decreased DNA repair status was strongly related to disease at diagnosis, but after the follow-up was no longer detectable. We have characterized a set of DNA repair-related parameters, which blood levels could distinguish between a condition of acute CRC versus disease in remission. The mRNA levels of six DNA repair genes (*LIG3*, *RPA3*, *CDK7*, *DDB2*, *NBN*, and *CHEK2*) together with NER capacity, if verified on a larger and independent population, might represent a panel of CRC related biomarkers.

#### DNA Repair in Relation to Therapy

NER capacity was increased upon tumor resection in all patients, but this trend was statistically significant only in patients administered to chemotherapy. In this context it is noteworthy that the *P* values observed for the increase in DNA repair in untreated patients were of borderline significance. An increase in the probability of these findings by enlarging the study group cannot be ruled out. Therefore, it is difficult at present to clearly distinguish whether the enhancement of NER capacity is a consequence of surgical tumor elimination, a defense reaction of normal cells against a systemic treatment, or both. Mutagenic activity of radio- and chemotherapeutics poses a challenge to not only the tumor, but also normal cells, that need to adjust their cellular functions in order to protect their genetic integrity. Indeed, several studies have shown that DNA repair processes are induced by genotoxic stress [20–23]. In our study group, an increase in the NER capacity at the end of treatment was not accompanied by an increase in the NER genes transcription, except for *XPB* and *XPB*. These two might be the main activators of NER function. In fact, endonucleases are critical components of NER and their knockdown dramatically reduces NER activity [24]. In this context, we cannot neglect the role of post-transcriptional [25,26] and post-translational [27–30] modifications in DNA repair regulation. At the mRNA level, only 3 out of 40 genes showed differential behavior between treated and untreated subjects, and those were involved again in the BER and NER pathways. BER gene *MUTYH* (MutY Homolog *E. coli*) increased its

expression over time in treated patients and remained stable in untreated patients. On the contrary, *POLB* (Polymerase Beta) involved in BER and NER gene *XPB* (Xeroderma Pigmentosum B) showed increased expression over time in untreated patients only. Although these differences did not seem to have any effect on the immediate response to therapy, it cannot be excluded that they may play some role in long-term survival. Above genes have been observed to be implicated in CRC development. Aberrant *MUTYH* glycosylase has been linked to one type of CRC [31], and *POLB* is mutated in about 50% of human cancers [32], including CRC [33]. Also, therapeutic downregulation of *POLB* activity was recently considered in order to meet better treatment response [34], and its mRNA levels have been proposed to be a prognostic indicator in CRC treatment [35].

So far, few studies have examined DNA repair in relation to anti-cancer therapy response and survival, but they usually sampled patients only once before therapy. Jewell et al. studied melanoma patients and reported that higher mRNA levels of DNA repair genes in biopsies were associated with a higher risk of relapse [36]. Wang et al. [37] found that elevated DNA repair activity in peripheral lymphocytes correlated with shorter survival in lung cancer. Similar tendencies were reported by Asakawa et al. [38] in breast cancer biopsies in which high DNA damage response was linked with poor response to neoadjuvant therapy. We were unable to analyze DNA repair parameters in relation to the patients' response to therapy at endpoint since no post-treatment tumor relapse was observed in the study group. Considering the small size of the study population, further stratifications for specific treatments would not reach sufficient statistical power to draw strong conclusions.

In summary, we described the dynamics of DNA repair in blood cells of CRC patients in a time frame of 1 yr. DNA repair downregulation in the presence of active disease, as reflected by quantitative PCR and functional assays, was centered on two excision repair pathways—BER and NER. One year after the diagnosis and successful treatment, the downregulation was not detectable anymore, and the patients exhibited a molecular pattern of DNA repair similar to that of healthy controls. DNA repair markers evaluated in blood cells can be used to distinguish between an acute and a post-treatment cancer-free condition, thus reflecting the disease activity in CRC patients.

#### ACKNOWLEDGMENTS

This study was supported by CZ GACR: GAP304/10/1286; CZ GACR: GAP 304/12/1585; CZ GACR: P304/11/P715; IGA: NT14329-3, and BIOCEV CZ.1.05/1.1.00/02.0109 from ERDF. The authors are grateful to Eric Van Emburgh and Beth O'Brien for their appreciable technical help.

#### REFERENCES

1. Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. *Int J Cancer* 2008; 127:2893–2917.
2. de Gramont A, Chibaudel B, Larsen AK, et al. The evolution of adjuvant therapy in the treatment of early-stage colon cancer. *Clin Colorectal Cancer* 2011;10:218–226.
3. Longley DB, Allen WL, Johnston PG. Drug resistance, predictive markers and pharmacogenomics in colorectal cancer. *Biochim Biophys Acta* 2006;1766:184–196.
4. Slyskova J, Naccarati A, Pardini B, et al. Differences in nucleotide excision repair capacity between newly diagnosed colorectal cancer patients and healthy controls. *Mutagenesis* 2012;27:225–232.
5. Herrera M, Dominguez G, Garcia JM, et al. Differences in repair of DNA cross-links between lymphocytes and epithelial tumor cells from colon cancer patients measured in vitro with the comet assay. *Clin Cancer Res* 2009;15:5466–5472.
6. Slyskova J, Korenkova V, Collins AR, et al. Functional, genetic, and epigenetic aspects of base and nucleotide excision repair in colorectal carcinomas. *Clin Cancer Res* 2012;18:5878–5887.
7. Saebo M, Skjelbred CF, Nexø BA, et al. Increased mRNA expression levels of ERCC1, OGG1 and RAI in colorectal adenomas and carcinomas. *BMC Cancer* 2006;6:208.
8. Yu J, Mallon MA, Zhang W, et al. DNA repair pathway profiling and microsatellite instability in colorectal cancer. *Clin Cancer Res* 2006;12:5104–5111.
9. Wyatt MD, Wilson DM III. Participation of DNA repair in the response to 5-fluorouracil. *Cell Mol Life Sci* 2009;66:788–799.
10. Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: The role of DNA repair pathways. *Clin Cancer Res* 2008;14:1291–1295.
11. Slyskova J, Naccarati A, Polakova V, et al. DNA damage and nucleotide excision repair capacity in healthy individuals. *Environ Mol Mutagen* 2011;52:511–517.
12. [http://sciencepark.mdanderson.org/labs/wood/DNA\\_Repair\\_Genes.html#NER](http://sciencepark.mdanderson.org/labs/wood/DNA_Repair_Genes.html#NER)
13. Benhamou S, Sarasin A. Variability in nucleotide excision repair and cancer risk: A review. *Mutat Res* 2000;462:149–158.
14. Gaivao I, Piasek A, Brevik A, et al. Comet assay-based methods for measuring DNA repair in vitro; estimates of inter- and intra-individual variation. *Cell Biol Toxicol* 2009;25:45–52.
15. Vogel U, Møller P, Dragsted L, et al. Inter-individual variation, seasonal variation and close correlation of OGG1 and ERCC1 mRNA levels in full blood from healthy volunteers. *Carcinogenesis* 2002;23:1505–1509.
16. Hatt L, Loft S, Risom L, et al. OGG1 expression and OGG1 Ser326Cys polymorphism and risk of lung cancer in a prospective study. *Mutat Res* 2008;639:45–54.
17. Vogel U, Nexø BA, Tjønneland A, et al. ERCC1, XPD and RAI mRNA levels in lymphocytes are not associated with lung cancer risk in a prospective study of Danes. *Mutat Res* 2006; 593:88–96.
18. Paz-Elizur T, Krupsky M, Blumenstein S, et al. DNA repair activity for oxidative damage and risk of lung cancer. *J Natl Cancer Inst* 2003;95:1312–1319.
19. Kolch W, Neuss C, Pelzing M, et al. Capillary electrophoresis-mass spectrometry as a powerful tool in clinical diagnosis and biomarker discovery. *Mass Spectrom Rev* 2005;24:959–977.
20. Vodicka P, Tuimala J, Stetina R, et al. Cytogenetic markers, DNA single-strand breaks, urinary metabolites, and DNA repair rates in styrene-exposed lamination workers. *Environ Health Persp* 2004;112:867–871.
21. Hanawalt PC. Subpathways of nucleotide excision repair and their regulation. *Oncogene* 2002;21:8949–8956.
22. Roos WP, Kaina B. DNA damage-induced cell death: From specific DNA lesions to the DNA damage response and apoptosis. *Cancer Lett* 2013;332:237–248.
23. Ljungman M. Activation of DNA damage signaling. *Mutat Res* 2005;577:203–216.

24. Graf N, Ang WH, Zhu G, et al. Role of endonucleases XPF and XPG in nucleotide excision repair of platinated DNA and cisplatin/oxaliplatin cytotoxicity. *Chembiochem* 2011;12:1115–1123.
25. Wouters MD, van Gent DC, Hoeijmakers JH, et al. MicroRNAs, the DNA damage response and cancer. *Mutat Res* 2011;717:54–66.
26. Hu H, Gatti RA. MicroRNAs: New players in the DNA damage response. *J Mol Cell Biol* 2011;3:151–158.
27. Swartzlander DB, Bauer NC, Corbett AH, et al. Regulation of base excision repair in eukaryotes by dynamic localization strategies. *Prog Mol Biol Transl Sci* 2012;110:93–121.
28. Sugawara K. Regulation of damage recognition in mammalian global genomic nucleotide excision repair. *Mutat Res* 2010;685:29–37.
29. Liu L, Lee J, Zhou P. Navigating the nucleotide excision repair threshold. *J Cell Physiol* 2010;224:585–589.
30. Fan J, Wilson DM III. Protein-protein interactions and posttranslational modifications in mammalian base excision repair. *Free Radic Biol Med* 2005;38:1121–1138.
31. Chow E, Thirlwell C, Macrae F, et al. Colorectal cancer and inherited mutations in base-excision repair. *Lancet Oncol* 2004;5:600–606.
32. Illuzzi JL, Wilson DM III. Base excision repair: Contribution to tumorigenesis and target in anticancer treatment paradigms. *Curr Med Chem* 2012;19:3922–3936.
33. Lang T, Maitra M, Starcevic D, et al. A DNA polymerase beta mutant from colon cancer cells induces mutations. *Proc Natl Acad Sci U S A* 2004;101:6074–6079.
34. Goellner EM, Svilar D, Almeida KH, et al. Targeting DNA polymerase ss for therapeutic intervention. *Curr Mol Pharmacol* 2012;5:68–87.
35. Iwatsuki M, Mimori K, Yokobori T, et al. A platinum agent resistance gene, POLB, is a prognostic indicator in colorectal cancer. *J Surg Oncol* 2009;100:261–266.
36. Jewell R, Conway C, Mitra A, et al. Patterns of expression of DNA repair genes and relapse from melanoma. *Clin Cancer Res* 2010;16:5211–5221.
37. Wang LE, Yin M, Dong Q, et al. DNA repair capacity in peripheral lymphocytes predicts survival of patients with non-small-cell lung cancer treated with first-line platinum-based chemotherapy. *J Clin Oncol* 2011;29:4121–4128.
38. Asakawa H, Koizumi H, Koike A, et al. Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins. *Breast Cancer Res* 2010;12:R17.

#### SUPPORTING INFORMATION

Additional supporting information may be found in the online version of this article at the publisher's web-site.